Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization

Cancer Research

Volumn 71, Issue 12, 2011, Pages 4214-4225

  Nardo, Giorgia ^a   Favaro, Elena ^a,g   Curtarello, Matteo ^b   Moserle, Lidia ^a,c   Zulato, Elisabetta ^b   Persano, Luca ^a   Rossi, Elisabetta ^a   Esposito, Giovanni ^b   Crescenzi, Marika ^b   Casanovas, Oriol ^c   Sattler, Ulrike ^d   Mueller Klieser, Wolfgang ^d   Biesalski, Barbara ^d   Thews, Oliver ^e   Canese, Rossella ^f   Iorio, Egidio ^f   Zanovello, Paola ^a   Amadori, Alberto ^a,b   Indraccolo, Stefano ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; FLUORODEOXYGLUCOSE F 18; GLUTAMIC ACID; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTIC ACID; MONOCLONAL ANTIBODY A4.6.1; MONOCLONAL ANTIBODY DC101; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CELL SWELLING; CELL VIABILITY; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME MODIFICATION; ENZYME PHOSPHORYLATION; GENE SILENCING; GLUCOSE INTAKE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; METABOLIC PARAMETERS; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR CELL; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VOLUME;

ADENYLATE KINASE; ANIMALS; CELL LINE, TUMOR; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MICE; NEOPLASMS, EXPERIMENTAL; PHENOTYPE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79958866010     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0242     Document Type: Article

References (47)

1. Cao Y. Angiogenesis: what can it offer for future medicine? Exp Cell Res 2010;316:1304-8.
2. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009;6:395-404.
3. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer; 8:592-603.
4. Cao Y. Off-tumor target-beneficial site for antiangiogenic cancer therapy? Nat Rev Clin Oncol 2010;7:604-8.
5. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38.
6. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-45. (Pubitemid 47338181)
7. Fenton BM, Paoni SF, Ding I. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother Oncol 2004;72:221-30. (Pubitemid 39024597)
8. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006;66:3639-48.
9. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63. (Pubitemid 40017699)
10. Grothey A, Galanis E. Targeting angiogenesis: progress with anti- VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6: 507-18.
11. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40. (Pubitemid 43108832)
12. Favaro E, Nardo G, Persano L, Masiero M, Moserle L, Zamarchi R, et al. Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death. Am J Pathol 2008;173:1186-201.
13. Papandreou I, Krishna C, Kaper F, Cai D, Giaccia AJ, Denko NC. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res 2005;65:3171-8. (Pubitemid 40524598)
14. Steinbach JP, Wolburg H, Klumpp A, Probst H, Weller M. Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. Cell Death Differ 2003;10:823-32. (Pubitemid 36850243)
15. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009;15:5020-5.
16. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18:3495-502.
17. 18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000;27: 1778-85.
18. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, et al. Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 2009;9:307.
19. Walenta S, Schroeder T, Mueller-Klieser W. Metabolic mapping with bioluminescence: basic and clinical relevance. Biomol Eng 2002;18: 249-62. (Pubitemid 34158559)
20. Walenta S, Schroeder T, Mueller-Klieser W. Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem 2004;11:2195-204. (Pubitemid 38967739)
21. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005;65:613-21.
22. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80. (Pubitemid 40216420)
23. Morse DL, Galons JP, Payne CM, Jennings DL, Day S, Xia G, et al. MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed 2007;20:602-14. (Pubitemid 47499995)
24. Sala E, Priest AN, Kataoka M, Graves MJ, McLean MA, Joubert I, et al. Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development. Eur Rad 2010;20:491-6.
25. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 2004;29:18-24. (Pubitemid 38068476)
26. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007;47:185-210.
27. Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009;14:378-90.
28. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
29. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009;9:563-75.
30. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Procl Natl Acad Sci USA 2004;101:3329-35. (Pubitemid 38338195)
31. Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 2009;326:1707-11.
32. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008;13:11-22. (Pubitemid 350309738)
33. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206. (Pubitemid 38903223)
34. Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J, et al. 5′-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 2006;26:5336-47. (Pubitemid 44036203)
35. Carretero J, Medina PP, Blanco R, Smit L, Tang M, Roncador G, et al. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 2007;26:1616-25. (Pubitemid 46398737)
36. Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, et al. MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J 2003;22:5102-14. (Pubitemid 37222030)
37. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG, Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147-58.
38. Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu CL, et al. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci USA 2009;106:11137-42.
39. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
40. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL, et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 2005;24:4165-73. (Pubitemid 40961771)
41. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71. (Pubitemid 350237599)
42. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6. (Pubitemid 350232248)
43. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009;100:1-7.
44. Ledermann JA, Raja FA. Targeted trials in ovarian cancer. Gynecol Oncol 2010;119:151-6.
45. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-77.
46. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002;62:3659-62. (Pubitemid 34728843)
47. Matsumura A, Isobe T, Takano S, Kawamura H, Anno I. Non-invasive quantification of lactate by proton MR spectroscopy and its clinical applications. Clin Neurol Neurosurg 2005;107:379-84. (Pubitemid 40980381)